Photodynamic therapy in neurosurgery: a review.
Photodynamic therapy (PDT) has been investigated extensively, both experimentally and clinically, as an adjunctive treatment in the neuro-oncological field. It is based on the more selective accumulation of a photosensitizer in malignant than normal tissue with low systemic toxicity. Subsequent light activation induces photo-oxidation, followed by selective tumour destruction via vascular and direct cellular mechanisms. Malignant brain tumours carry a lethal prognosis with a median survival of 15 months despite surgery, radiotherapy and chemotherapy. PDT is therefore a logical therapeutic concept for brain tumours infiltrating into normal brain. In this review, all the available data on patients treated with haematoporphyrin derivative-mediated PDT are critically analysed. Over 310 patients have been reported in the literature suffering from primary or recurrent malignant brain tumours which were treated with PDT following tumour resection in open clinical phase I/II trials. This number includes 58 patients treated at our own institution. Variations in the treatment protocols make evaluation scientifically difficult; however, there is a clear trend of increased median survival after surgical resection and one single photodynamic treatment. PDT is generally well tolerated and side effects consist of moderate increased intracranial pressure and prolonged skin sensitivity to direct sunlight. The current available data indicate that PDT is a safe treatment, which is well tolerated by the patients and yields an improvement in survival of those with malignant brain tumours. Conclusive information can be expected from controlled clinical trials which are currently being designed. The results raise the hope that PDT will be a valuable addition to the armamentarium for the treatment of cerebral malignancies.
Kostron
H
H
Department of Neurosurgery, University of Innsbruck, Austria.
Obwegeser
A
A
Jakober
R
R
D001706:Biopsy; D001921:Brain / Q000187:drug effects / Q000528:radiation effects; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D005909:Glioblastoma / Q000188:drug therapy / Q000601:surgery; D017324:Hematoporphyrin Derivative / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000601:surgery; D009493:Neurosurgery / Q000379:methods*; D010778:Photochemotherapy / Q000706:statistics & numerical data*
D017324:Hematoporphyrin Derivative